Table 1.

Total Sample Means and (Standard Deviations) and Parameter Estimates from the Regression Analyses Examining the Relationship between Buprenorphine Dose and 10 Neonatal Clinical Outcomes (N=58)

Outcome Variable	Mean (SD)	b	SE	AOR	95% CI	p
Total amount of morphine for NAS† (mg)	1.7 (3.0)			.98	.90, 1.07	.70
Duration of treatment for NAS† (days)	4.6 (6.2)			.99	.92, 1.06	.78
Duration of neonatal hospital stay (days)	10.1 (7.0)			.99	.97, 1.03	.95
Gestational age at delivery (weeks)	39.1 (2.2)			1.00	.99, 1.00	.82
Apgar score at 1 minute	8.1 (1.6)			1.00	.99, 1.02	.86
Apgar score at 5 minutes	9.0 (1.1)			1.00	.99, 1.01	.99
NAS peak score†	11.0 (3.4)	−.05	.07			.50
Neonatal head circumference at birth (cm)†	33.8 (1.9)	.01	.04			.78
Neonatal weight at birth (g)	3096.9 (561.2)	1.34	11.93			.91
Neonatal length at birth (cm)†	49.8 (2.7)	.04	.06			.48

Notes. Means do not equal values found in Table 2 of Jones et al. (2010), because the latter means are model-derived marginal means from a model that includes site and the methadone condition. SD = Standard Deviation. NAS = Neonatal Abstinence Syndrome. b = unstandardized partial regression coefficient. SE = Standard Error. AOR = Adjusted Odds Ratio (adjusted for the fixed site factor), 95% CI = 95% Confidence Interval.

^†One case is missing data for this variable.